A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ribavirin (Primary)
- Indications Head and neck cancer
- Focus Pharmacodynamics
Most Recent Events
- 29 Oct 2020 Biomarkers information updated
- 18 Dec 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 18 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.